MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02350nam a2200277Ia 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
MX-MdCICY |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20250625162449.0 |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
CICY |
| 090 ## - LOCALLY ASSIGNED LC-TYPE CALL NUMBER (OCLC); LOCAL CALL NUMBER (RLIN) |
|---|
| Classification number (OCLC) (R) ; Classification number, CALL (RLIN) (NR) |
B-20489 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
250602s9999 xx |||||s2 |||| ||und|d |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Nutraceuticals and network pharmacology approach for acute kidney injury: A review from the drug discovery aspect |
| 490 0# - SERIES STATEMENT |
|---|
| Volume/sequential designation |
Fitoterapia, 168, p.105563, 2023 |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc. |
Acute kidney injury (AKI)has become a global health issue, with ?12 million reports yearly, resulting in a persistent increase in morbidity and mortality rates. AKI pathophysiology is multifactorial involving oxidative stress, mitochondrial dysfunction, epigenetic modifications, inflammation, and eventually, cell death. Hence, therapies able to target multiple pathomechanisms can aid in AKI management. To change the drug discovery framework from "one drug, one target" to "multicomponent, multitarget," network pharmacology is evolving as a next-generation research approach. Researchers have used the network pharmacology approach to predict the role of nutraceuticals against different ailments including AKI. Nutraceuticals (herbal products, isolated nutrients, and dietary supplements)belong to the pioneering category of natural products and have shown protective action against AKI. Nutraceuticals have recently drawn attention because of their ability to provide physiological benefits with less toxic effects. This review emphasizes the nutraceuticals that exhibited renoprotection against AKI and can be used either as monotherapy or adjuvant with conventional therapies to boost their effectiveness and lessen the adverse effects. Additionally, the study sheds light on the application of network pharmacology as a cost-effective and time-saving approach for the therapeutic target prediction of nutraceuticals against AKI. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
ACUTE KIDNEY INJURY |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
CHRONIC KIDNEY DISEASE |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
DRUG DISCOVERY |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
NETWORK PHARMACOLOGY |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
NUTRACEUTICALS |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
POLYPHARMACOLOGY |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Dagar, N. |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Kale, A. |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Jadhav, H. R. |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Gaikwad, A. B. |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="https://drive.google.com/file/d/1wdnYfw7AVXSvTIW3NnOxXiKDGSb4o7yR/view?usp=drivesdk">https://drive.google.com/file/d/1wdnYfw7AVXSvTIW3NnOxXiKDGSb4o7yR/view?usp=drivesdk</a> |
| Public note |
Para ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Clasificación local |
| Koha item type |
Documentos solicitados |
